NOC2L联合SLFN11检测在肝癌病情及预后评估中的临床价值

何建新; 张洪彬; 楼韵燕

doi:10.16766/j.cnki.issn.1674-4152.004010

NOC2L联合SLFN11检测在肝癌病情及预后评估中的临床价值

doi: 10.16766/j.cnki.issn.1674-4152.004010

1.
义乌市中心医院检验科，浙江义乌 322000
2.
义乌市中心医院放射科

基金项目:

浙江省医药卫生科技计划项目 2024KY507

详细信息

通讯作者:
楼韵燕，E-mail：zoe201305@163.com

中图分类号: R735.7
计量
- 文章访问数: 7
- HTML全文浏览量: 3
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2024-10-09
- 网络出版日期: 2025-08-14

Clinical value of NOC2L combined with SLFN11 detection in the evaluation of liver cancer condition and prognosis

1.
Department of Laboratory Medicine, Yiwu Central Hospital, Yiwu, Zhejiang 322000, China

摘要

摘要: 目的 NOC2L和SLFN11与恶性肿瘤发病机制密切相关，本研究旨在分析NOC2L联合SLFN11检测在肝癌中的临床价值。方法检测2020年1月—2021年12月义乌市中心医院诊治的95例肝癌患者(HCC组)及51例肝脏良性疾病患者(对照组)NOC2L、SLFN11表达水平，并分析与预后、生存期的关系。结果 HCC组肿瘤组织NOC2L高于癌旁组织和对照组(1.26±0.25 vs.0.72±0.11、0.69±0.13，F=264.577，P < 0.001)，SLFN11低于癌旁组织和对照组(0.78±0.12 vs.0.96±0.17、0.98±0.15，F=46.396，P < 0.001)。HCC组NOC2L表达与病理分级、原发肿瘤T分期、转移淋巴结数、远处转移及TNM分期均呈正相关关系(均r_s>0，P < 0.05)，SLFN11表达与上述项目均呈负相关关系(均r_s < 0，P < 0.05)。SLFN11联合NOC2L检测预测肝癌预后不良的效能高于NOC2L、SLFN11单独预测(P < 0.05)。NOC2L≥1.26、SLFN11≤0.78为肝癌预后不良的独立危险因素(P < 0.05)。NOC2L≥1.26、SLFN11≤0.78患者中位生存期低于NOC2L＜1.26或SLFN11>0.78的患者(log-rank χ²=14.618，P < 0.001)。结论肝癌NOC2L和SLFN11表达可为肝癌病情及预后评估提供客观证据，两者联合可显著提高预测病情及预后的价值。
- 肝癌 /
- NOC2类核仁相关转录抑制因子 /
- Schlafen家族成员11
Abstract: Objective NOC2L and SLFN11 are closely related to the pathogenesis of malignant tumors. The clinical value of NOC2L combined with SLFN11 detection in liver cancer was studied. Methods The expression of NOC2L and SLFN11 was detected in 95 patients with liver cancer (HCC group) and 51 patients with benign liver diseases (control group) treated in Yiwu Central Hospital from January 2020 to December 2021, and the relationship with prognosis and survival was analyzed. Results NOC2L in tumor tissue of HCC group was higher than that in adjacent tissue and control group (1.26±0.25 vs. 0.72±0.11, 0.69±0.13, F=264.577, P < 0.001), while SLFN11 was lower than that in adjacent tissue and control group (0.78±0.12 vs. 0.96±0.17, 0.98±0.15, F=46.396, P < 0.001). In the HCC group, NOC2L expression was positively correlated with pathological grade, primary tumor T stage, number of metastatic lymph nodes, distant metastasis, and TNM stage (all r_s>0, P < 0.05), while SLFN11 expression was negatively correlated (all r_s < 0, P < 0.05). The efficacy of SLFN11 combined with NOC2L detection in predicting poor prognosis of liver cancer was higher than that of NOC2L and SLFN11 alone (P < 0.05). NOC2L≥1.26 and SLFN11≤0.78 were independent risk factors for poor prognosis of liver cancer (P < 0.05). The median survival of patients with NOC2L≥1.26 and SLFN11≤0.78 was lower than that of patients with NOC2L < 1.26 or SLFN11>0.78 (log-rank χ²=14.618, P < 0.001). Conclusion The expression of NOC2L and SLFN11 in liver cancer can provide objective evidence for the evaluation of liver cancer disease and prognosis. The combination of the two can significantly improve the value of predicting disease and prognosis.
- Liver cancer /
- NOC2 like nucleolar associated transcriptional repressor /
- Schlafen family member 11

HTML全文

图 1 不同NOC2L、SLFN11表达情况肝癌患者Kaplan-Meier生存分析

Figure 1. Kaplan-Meier survival analysis of HCC patients with different NOC2L and SLFN11 expression levels

下载: 全尺寸图片幻灯片

表 1 HCC组与对照组基线资料比较

Table 1. Comparison of baseline clinical data of subjects in the HCC group and the control group

组别	例数	性别(男性/女性，例)	年龄(x±s，岁)	卡氏评分(x±s，分)	BMI (x±s)	肝炎病史(有/无，例)	家族史(有/无，例)
HCC组	95	59/36	56.72±8.11	92.37±4.09	22.56±3.04	70/25	15/80
对照组	51	33/18	56.28±8.46	92.31±4.25	22.31±3.15	35/16	9/42
统计量		0.096^a	0.308^b	0.083^b	0.468^b	0.420^a	0.083^a
P值		0.756	0.759	0.934	0.641	0.517	0.773
注：^a为χ²值，^b为t值。

下载: 导出CSV

表 2 不同临床病理特征肝癌患者肿瘤组织NOC2L、SLFN11表达比较(x±s)

Table 2. Comparison of NOC2L and SLFN11 expressions in liver cancer tumor tissues with different clinicopathological characteristics(x±s)

项目	例数	NOC2L	t值	P值	SLFN11	t值	P值
性别			0.587	0.559		0.774	0.441
男性	59	1.24±0.23			0.77±0.11
女性	36	1.27±0.26			0.79±0.14
年龄			0.585	0.561		1.091	0.278
≥60岁	43	1.25±0.22			0.76±0.11
< 60岁	52	1.28±0.27			0.79±0.15
肿瘤位置			0.414	0.680		0.722	0.472
右半肝	50	1.27±0.24			0.77±0.13
左半肝	45	1.25±0.23			0.79±0.14
病理类型			0.333	0.740		0.645	0.521
肝细胞癌	86	1.28±0.26			0.76±0.13
其他	9	1.25±0.22			0.79±0.16
病理分级			2.159	0.334		4.168	< 0.001
1~2级	60	1.21±0.22			0.82±0.14
3级	35	1.32±0.27			0.71±0.09
原发肿瘤T分期			2.316	0.023		4.753	< 0.001
T1~T2	51	1.19±0.18			0.84±0.15
T3~T4	44	1.29±0.24			0.72±0.08
转移淋巴结数			3.062	0.003		4.652	< 0.001
N0	68	1.17±0.19			0.83±0.14
N1	27	1.32±0.27			0.69±0.11
远处转移			2.228	0.028		3.905	< 0.001
无	81	1.19±0.18			0.84±0.15
有	14	1.31±0.22			0.68±0.07
TNM分期			4.054	< 0.001		5.730	< 0.001
Ⅰ~Ⅱ期	74	1.17±0.14			0.85±0.14
Ⅲ~Ⅳ期	21	1.35±0.28			0.66±0.11

下载: 导出CSV

表 3 肿瘤组织NOC2L、SLFN11表达与肝癌临床病理特征的相关性

Table 3. Correlation between NOC2L and SLFN11 expressions in tumor tissues and clinicopathological characteristics of liver cancer

项目	NOC2L		SLFN11
项目	r_s	P值	r_s	P值
病理分级	0.637	0.017	-0.704	0.036
原发肿瘤T分期	0.665	0.024	-0.681	0.015
转移淋巴结数	0.713	0.008	-0.639	0.021
远处转移	0.691	0.026	-0.626	0.005
TNM分期	0.634	0.031	-0.677	0.018

下载: 导出CSV

表 4 肝癌预后不良危险因素的多因素Cox回归分析

Table 4. Multivariate Cox regression analysis of risk factors for poor prognosis of liver cancer

变量	B	SE	Waldχ²	P值	HR值	95% CI
NOC2L≥1.26	1.577	0.162	15.466	< 0.001	4.841	1.578~6.452
SLFN11≤0.78	1.451	0.149	14.023	< 0.001	4.267	1.311~6.057
注：赋值方法如下，预后良好=0，预后不良=1；NOC2L＜1.26=0，≥1.26=1；SLFN11>0.78=0，≤0.78=1。

下载: 导出CSV

表 5 NOC2L、SLFN11预测肝癌患者预后不良的灵敏度及特异度

Table 5. Sensitivity and specificity of NOC2L and SLFN11 in predicting poor prognosis of patients with liver cancer

项目	灵敏度	特异度	P值	SE	AUC	95% CI
NOC2L	0.656	0.614	0.017	0.078	0.675	0.415~1133
SLFN11	0.621	0.649	0.023	0.068	0.692	0.405~1.201
NOC2L联合SLFN11	0.856	0.877	0.005	0.095	0.874^ab	0.517~1.453
注：与NOC2L比较，^aP < 0.05；与SLFN11比较，^bP < 0.05。

下载: 导出CSV

参考文献(20)

[1]	童里, 郑小飞, 顾旺, 等. 细胞自噬在肝细胞肝癌中的研究现状[J]. 中华全科医学, 2023, 21(4): 672-676. doi: 10.16766/j.cnki.issn.1674-4152.002957 TONG L, ZHENG X F, GU W, et al. Research status of autophagy in hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2023, 21(4): 672-676. doi: 10.16766/j.cnki.issn.1674-4152.002957
[2]	ZHENG S, CHAN S W, LIU F, et al. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges[J]. Cancers (Basel), 2024, 16(8): 1582. DOI: 10.3390/cancers16081582.
[3]	凡丹丹, 高芳芳, 邹婧, 等. 喉癌肿瘤组织NOC2L、p53表达及其临床价值研究[J]. 疑难病杂志, 2024, 23(10): 1177-1181. doi: 10.3969/j.issn.1671-6450.2024.10.005 FAN D D, GAO F F, ZOU J, et al. Expression of NOC2L and p53 in laryngeal carcinoma tumor tissue and its clinical value[J]. Chinese Journal of Difficult and Complicated Cases, 2024, 23(10): 1177-1181. doi: 10.3969/j.issn.1671-6450.2024.10.005
[4]	KACZOROWSKI M, YLAYA K, CHŁOPEK M, et al. Immunohistochemical evaluation of Schlafen 11 (SLFN11) expression in cancer in the search of biomarker-informed treatment targets: a study of 127 entities represented by 6658 tumors[J]. Am J Surg Pathol, 2024(8): 35-52.
[5]	MU A, OKAMOTO Y, KATSUKI Y, et al. The role of SLFN11 in DNA replication stress response and its implications for the Fanconi anemia pathway[J]. DNA Repair (Amst), 2024, 141(4): 103733. DOI: 10.1016/j.dnarep.2024.103733.
[6]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. National Health Commission of the People's Republic of China Medical Administration. Diagnosis and treatment criteria for primary liver cancer (2019 edition)[J]. Journal of Hepatobiliary Diseases, 2020, 36(2): 277-292.
[7]	马倩, 李亚, 马艺钊, 等. 中药调控p53信号通路干预肺癌的作用机制研究进展[J]. 中国药房, 2024, 35(11): 1403-1407. MA Q, LI Y, MA Y Z, et al. Mechanism research progress of traditional Chinese medicine intervening in lung cancer by regulating p53 signaling pathway[J]. China Pharmacy, 2024, 35(11): 1403-1407.
[8]	李健, 金俊豪, 金艳花. JIB-04通过抑制组蛋白赖氨酸去甲基化酶4表达来调控MDM2/P53/SLC7A11/GPX4轴诱导肝癌细胞发生铁死亡[J]. 中国生物化学与分子生物学报, 2024, 40(8): 1144-1152. LI J, JIN J H, JIN Y H. JIB-04 Regulates the MDM2/P53/SLC7A11/GPX4 Signaling Axis to Induce Ferroptosis in Hepatocellular Carcinoma Cells by Inhibiting KDM4C Expression[J]. Chinese Journal of Biochemistry and Molecular Biology, 2024, 40(8): 1144-1152.
[9]	LI Y, WANG L, LIU X, et al. NIR promotes progression of colorectal cancer through regulating RB[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(1): 118856. DOI: 10.1016/j.bbamcr.2020.118856.
[10]	XU L, TAN A C, WINSLOW R L, et al. Merging microarray data from separate breast cancer studies provides a robust prognostic test[J]. BMC Bioinformatics, 2008, 9(7): 125.
[11]	KÖNIG P, EICHHORN J M, SUPARMAN E, et al. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells[J]. Biochim Biophys Acta Mol Basis Dis, 2024, 1870(8): 167448. DOI: 10.1016/j.bbadis.2024.167448.
[12]	SIMIC' I, GUZONJIC' A, KOTUR STEVULJEVIC' J, et al. Correlation of systemic inflammation parameters and serum SLFN11 in small cell lung cancer-a prospective pilot study[J]. Biomedicines, 2024, 12(5): 976.
[13]	WANG H X, ZHAO Z P, DU X Y, et al. SLFN11 promotes clear cell renal cell carcinoma progression via the PI3K/AKT signaling pathway[J]. Med Oncol, 2024, 41(2): 54.
[14]	ZHOU C, LIU C, LIU W, et al. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway[J]. Theranostics, 2020, 10(10): 4627-4643.
[15]	ZHOU C, WENG J, LIU C, et al. Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma[J]. Gastroenterology, 2023, 164(7): 1261-1278.
[16]	GOYAL H, PARWANI S, KAUR J. Deciphering the nexus between long non-coding RNAs and endoplasmic reticulum stress in hepatocellular carcinoma: biomarker discovery and therapeutic horizons[J]. Cell Death Discov, 2024, 10(1): 451.
[17]	张雅琼, 黄澜, 潘聪莹. 多种血液学标志物预测肝癌切除术后感染的临床价值[J]. 中国临床研究, 2024, 37(10): 1542-1546. ZHANG Y Q, HUANG L, PAN C Y. Clinical value of multiple hematological markers to predict infection after hepatic carcinectomy[J]. Chinese Journal of Clinical Research, 2024, 37(10): 1542-1546.
[18]	钟敏, 杨小莉. 肝硬化-肝癌恶性转化的相关机制及诊断生物标志物研究进展[J]. 公共卫生与预防医学, 2024, 35(5): 121-124. ZHONG M, YANG X L. Research progress on the related mechanism of malignant transformation of liver cirrhosis-hepatocellular carcinoma and diagnostic biomarkers[J]. Journal of Public Health and Preventive Medicine, 2024, 35(5): 121-124.
[19]	陈文亮, 徐细明. 肝癌早期诊断标志物的研究新进展[J]. 中国医药导报, 2023, 20(1): 40-44. CHEN W L, XU X M. New progress in the study of markers for the early diagnosis of liver cancer[J]. China Medical Herald, 2023, 20(1): 40-44.
[20]	周杰, 李敬东, 张立鑫, 等. Polo样激酶1在肝细胞肝癌中的作用及临床意义[J]. 安徽医学, 2023, 44(10): 1173-1179. ZHOU J, LI J D, ZHANG L X, et al. Polo-like kinase 1 Expression in hepatocellular carcinoma and its effect on cell proliferation[J]. Anhui Medical Journal, 2023, 44(10): 1173-1179.